Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Through our robust pipeline of first-in-class candidates and proprietary ADC platform, Igenica is accelerating the development and delivery of effective therapies that hold the potential to change the face of cancer treatment. Link

August 7, 2014

Igenica Biotherapeutics Awarded SBIR Grant for Next Generation Antibody Drug Conjugate Technology
READ MORE>>

March 25, 2014

Igenica Biotherapeutics to Present at the 21st Annual BioCentury Future Leaders In The Biotech Industry
READ MORE>>